Since WT1 overexpression appeared to play a functional role in predicting complete remission of the CN-AML patients especially when it is combined with the favorable NPM1mt/no FLT3ITD or the unfavorable FLT3ITD genotypes, we next examined the potential impact of WT1 overexpression on the disease-free survival (DFS) and the overall survival (OS) of the studied CN-AML patient cohort. This evidence concerns the gene WT1 and acute myeloid leukemia.